(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/057389 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/EP2022/077470

(22) International Filing Date:
03 October 2022 (03.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/251,916	04 October 2021 (04.10.2021)	US
21204879.7	26 October 2021 (26.10.2021)	EP
21217026.0	22 December 2021 (22.12.2021)	EP
63/321,955	21 March 2022 (21.03.2022)	US
63/390,855	20 July 2022 (20.07.2022)	US

(71) Applicant: **FORX THERAPEUTICS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors: **LUECKING, Ulrich**; Paula-Furst-Str. 2, 10317 Berlin (DE). **GOUTOPOULOS, Andreas**; 20 Fayette Street, Unit #2, Boston, Massachusetts 02116 (US). **TIAN, Jin**; WuXi App Tec (Wuhan) Co., Ltd., No. 666 GaoXin Road, WuHan East Lake High-tech Development Zone, Hubei, 430075 (CN). **SOTIRIOU, Sotirios**; Johanniterstrasse 5, 4056 Basel (CH). **IACOVINO, Luca**; Metzerstrasse 7, 4056 Basel (CH). **FREUDENMANN, Alena**; Maulbeerstrasse 83, 4058 Basel (CH). **QUEROLLE, Olivier**; c/o FoRx Therapeutics, Lichtstrasse 35, 4056 Basel (CH).

(74) Agent: **VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELTE MBB**; Siebertstr. 3, 81675 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/057389 A1

(54) Title: PARG INHIBITORY COMPOUNDS



(I)

(57) Abstract: The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, pharmaceutically acceptable salt or a prodrug thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as PARC inhibitors, and can be used in a method of treatment of a proliferative disorder, preferably of cancer.